Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
This is a multicenter clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers. Module A will enroll participants with advanced/metastatic solid tumors. Additional modules exploring other cancers may be added to the master protocol at a later date. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion).
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Mar 5, 2026 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Deciphera Pharmaceuticals, LLC
- Interventions being studied
- Drug: DCC-3084
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- General Inclusion Criteria ModA Part 1 and 2:
- Able to take oral medication
- If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements
- Adequate organ function and electrolytes
- Eastern Cooperative Oncology Group Performance Status (ECOG-PS) of 0 to 1 at Screening
- Has a life expectancy of more than 6 months
- In addition to these general inclusion criteria, participants must meet all the module cohort-specific inclusion criteria Inclusion Criteria ModA Part 1 Cohort Specific:
- Pathologically confirmed diagnosis of solid cancer and documentation of Kirsten rat sarcoma (KRAS), Harvey rat sarcoma virus (HRAS), neuroblastoma ras viral oncogene homolog (NRAS), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), v-raf murine sarcoma viral oncogene homolog C1(CRAF), and/or neurofibromatosis 1 (NF1) mutation
- Have exhausted all available standard of care therapies that are known to provide benefit for the participant's condition, as judged by the Investigator Inclusion Criteria ModA Part 2 Cohort Specific:
- Documented BRAF gene mutation
- Pathologically confirmed diagnosis with PD after at least one prior line of therapy in the advanced or metastatic setting
General
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Southern California - Norris Comprehensive Cancer CenterLos Angeles, California
- University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer CenterSan Francisco, California
- SCRI HealthONEDenver, Colorado
- SCRI Florida Cancer SpecialistsOrlando, Florida
- Dana-Farber Cancer InstituteBoston, Massachusetts
- Roswell Park Comprehensive Cancer CenterBuffalo, New York
- SCRI Oncology PartnersNashville, Tennessee
- NEXT OncologySan Antonio, Texas
- NEXT Oncology VirginiaFairfax, Virginia
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 5, 2026. Always confirm current availability with the study team.